Marien Hospital Duesseldorf

Düsseldorf 40479

2 studies enrolling now · 5 studies all time

What they study most

Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Immune Thrombocytopenic Purpura, Indolent Systemic Mastocytosis, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes (MDS), Myelofibrosis, Post-ET Myelofibrosis, Post-PV MF, Primary Myelofibrosis

Studies at this site

• Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation — Recruiting now
• Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib — Recruiting now
• A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy — Running, not enrolling
• Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis — Status unconfirmed
• A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) — Completed